# Selinexor

Selinexor (Nexpovio, Stemline Therapeutics B.V.) has 2 EU-approved indications in 1 tumour type.

## Approved indications

### Multiple myeloma

| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| None | + bortezomib and dexamethasone | 2nd line | After at least one prior therapy |
| None | + dexamethasone | 3rd line+ | After at least four prior therapies; refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, with disease progression on the last therapy |

## Products

### Nexpovio

- Company: Stemline Therapeutics B.V.
- Target: Exportin 1 (XPO1) inhibitor
- Class: Other antineoplastic agents
- ATC: L01XX66
- EU approval: 26 Mar 2021
- Label revised: 5 Aug 2026
- SmPC (EN): https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf
- Fachinformation (DE): https://www.ema.europa.eu/de/documents/product-information/nexpovio-epar-product-information_de.pdf
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio

Mechanism (SmPC section 5.1): Selinexor selectively blocks exportin 1 (XPO1), leading to nuclear accumulation of tumour suppressor proteins, cell cycle arrest, down-regulation of oncoproteins, and cancer cell apoptosis.

## Label wording

- **Selinexor** (Nexpovio), Multiple myeloma, 2nd line: “in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf)
- **Selinexor** (Nexpovio), Multiple myeloma, 3rd line+: “in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/drugs/selinexor